Approximately one-fifth of ischemic strokes occur during sleep and are not detected until patients wake up with neurological deficits.[2,3] Stroke Screening and Prevention Program could improve the effective control rate of primary diseases in high-risk groups.[4] However, Recombinant tissue plasminogen activator (rt-PA) is currently the unique approved treatment for acute ischemic stroke and is restricted to use within 4.5 hours of ischemic stroke onset.[5] We typically define the last seen normal time as the time of stroke onset. The gene discussed is PLAT; the disease is stroke disorder.